Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Actilyse

Actilyse is a medicine containing the active ingredient(s) alteplase. On this page you will find out more about Actilyse, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.

Active ingredient in this medicine: alteplase

Pack size information

Please select the pack size from the options directly below to view information on the medicine.

Information for medicine and pack size:
Actilyse (1 x 10 mg vial, 1 x 10 mL inert diluent vial), 1 pack

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

Myocardial Infarction: Actilyse is indicated for intravenous use in adults for the lysis of suspected occlusive coronary artery thrombi associated with evolving transmural myocardial infarction. Treatment should be initiated as soon as possible after the onset of symptoms. The treatment can be initiated within 12 hours of symptom onset. Pulmonary Embolism: Actilyse is also indicated in patients with acute massive pulmonary embolism in whom thrombolytic therapy is considered appropriate. Acute Ischaemic Stroke; Actilyse is indicated for thrombolytic treatment of acute ischaemic stroke. Treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging techniques (e.g. cranial computerised tomography or other diagnostic imaging method sensitive for the presence of haemorrhage). The treatment effect is time-dependent; therefore earlier treatment increases the probability of a favourable outcome.

Table of characteristics
Table of characteristics
Active ingredient
Medicine schedule
1 vial of 10mg powder: Prescription Only Medicine, or Prescription Animal Remedy
1 vial of 10mL diluent: Not scheduled. Not considered by committee
Part 1
Part 1
Visual appearance A clear liquid free from particles.
Dosage Form Diluent, not applicable
Route of administration Intravenous
Part 2
Part 2
Visual appearance Colourless to pale yellow cake of powder.
Dosage Form Injection, powder for
Route of administration Intravenous

There is one type of pack available.

Pack type 1
Pack type 1
Type Vial
Storage temperature Store below 30 degrees Celsius
Storage conditions Protect from Light
Life time 2 Years
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site

The information displayed on this page is authored by Healthdirect Australia, or obtained from trusted sources.

Need more information?

These trusted information partners have more on this topic.

Found 4 results

Actilyse | myVMC

Actilyse is used to treat heart attack, pulmonary embolism and ischaemic stroke. It contains alteplase, a medicine that converts plasminogen to plasmin.

Read more on myVMC – Virtual Medical Centre website

Actilyse Powder for injection -

Actilyse Powder for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Actilyse 50 mg (alteplase) information | myVMC

Actilyse 50 mg (alteplase) is used to treat various conditions caused by blood clots such as myocardial infarction, pulmonary embolism, and stroke.

Read more on myVMC – Virtual Medical Centre website

Pulmonary embolism

Pulmonary embolism (PE) happens when a blood clot blocks one of the arteries in the lungs. Find out about the causes, diagnosis, treatment and prevention of PE.

Read more on myDr website

Healthdirect 24hr 7 days a week hotline

24 hour health advice and information you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo